Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27259595 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HPGDFGFR3KDRNPC1 | |
| SCHEMBL15551629 | 0.79 | ALDH1A1 (0.45) | ALDH1A1HPGDFGFR3KDRNPC1 | |
| SCHEMBL12565424 | 0.76 | ALDH1A1 (0.52) | ALDH1A1HPGDFGFR3KDR | |
| SCHEMBL30908140 | 0.76 | ALDH1A1 (0.52) | ALDH1A1HPGDFGFR3KDR | |
| SCHEMBL1932985 | 0.76 | ALDH1A1 (0.42) | ALDH1A1HPGDFGFR3KDRSMN1; SMN2 | |
| SCHEMBL4540262 | 0.76 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9ASMN1; SMN2ADORA3 | |
| SCHEMBL15885419 | 0.76 | ALDH1A1 (0.42) | ALDH1A1HPGDFGFR3KDRNPC1 | |
| SCHEMBL15690548 | 0.76 | ALDH1A1 (0.42) | ALDH1A1HPGDFGFR3KDRNPC1 | |
| SCHEMBL27259229 | 0.72 | BACE1 (0.33) | CRHBPCRHR2 | |
| SCHEMBL15043760 | 0.72 | ADORA3 (0.39) | ALDH1A1HPGDFGFR3KDRADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020123453-A2 | ALK5 INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-06-18 | — | — | WO | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682141-B2 | Combination of kinase inhibitors and uses thereof | INTELLIKINE LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | INTELLIKINE LLC | 2016-08-18 | — | — | US | disclosed |
| EP-2575462-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-2575462-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2016-06-22 | — | — | EP | disclosed |
| US-9359352-B2 | Substituted benzimidazoles as PI3 kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359352-B2 | Substituted benzimidazoles as PI3 kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359352-B2 | Substituted benzimidazoles as PI3 kinase inhibitors | INTELLIKINE LLC (US) | 2016-06-07 | — | — | US | disclosed |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2013-10-03 | — | — | US | disclosed |
| WO-2013078441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013078441-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-30 | — | — | WO | disclosed |
| WO-2013071264-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-05-16 | — | — | WO | disclosed |
| EP-2575462-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Intellikine, LLC (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | INTELLIKINE LLC (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012148540-A1 | COMBINATION OF KANASE INHIBITORS AND USES THREOF | INTELLIKINE, LLC (US) | 2012-11-01 | — | — | WO | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011149937-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235758-A1 | COMBINATION OF MTOR INHIBITORS AND PI3-KINASE INHIBITORS, AND USES THEREOF | MTOR, RPTOR, RICTOR | ALDH1A1 4784/4885HPGD 4206/4885FGFR3 709/4885 |
| US-20130261102-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | ALDH1A1 2379/4885HPGD 629/4885FGFR3 726/4885 |
| US-20120294930-A1 | COMBINATION OF KINASE INHIBITORS AND USES THEREOF | MTOR, AKT2, MTMR1 | ALDH1A1 4563/4885HPGD 3896/4885FGFR3 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.